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An Escherichia coli isolate with New Delhi metallo-β-
lactamase was isolated from a patient with pyelonephritis 
and prostatitis who returned to Canada after recent hospi-
talization in India. The patient was successfully treated with 
ertapenem and fosfomycin. This patient highlights the role 
of international travel in the spread of antimicrobial drug re-
sistance and blaNDM-1.
T
he  Enterobacteriaceae, particularly Escherichia coli 
and Klebsiella pneumoniae, are among the most com-
mon causes of serious hospital- and community-acquired 
bacterial infections in humans. Resistance to antimicrobial 
agents in these species has become increasingly prevalent. 
Of special concern is the development of resistance to the 
carbapenems; this development is caused by bacterial car-
bapenemases. These drugs are often the last line of effec-
tive therapy for treating infections caused by multidrug-
resistant Enterobacteriaceae. Three types of β-lactamases 
inactivate the carbapenems: K. pneumoniae carbapenemas-
es, metallo-β-lactamases (MBLs), and oxacillinases. The 2 
most reported MBLs are the VIM and IMP types, which 
until recently have been mostly associated with Pseudomo-
nas aeruginosa and Acinetobacter spp., although VIM-2 
has spread among Enterobacteriaceae in Greece and, to a 
lesser extent, Italy (1).
Recently, a new type of MBL, New Delhi metallo-β-
lactamase (NDM-1), in bacteria (K. pneumoniae and E. 
coli) recovered from a patient from Sweden who was hos-
pitalized in New Delhi, India, was described (2).We char-
acterized a carbapenem-resistant E. coli isolate from the 
urine of a patient with pyelonephritis and prostatitis who 
returned to Canada after recent hospitalization while visit-
ing India.
The Study
A 32-year-old man was admitted to the medical ward 
of a hospital in Mysore, southwestern India, during 2010, 
with hyperglycemia and upper urinary tract infection (UTI). 
His underlying diabetes mellitus was stabilized, but his 
UTI did not improve after 5 days of ciproﬂ  oxacin. He was 
transferred to a hospital in Alberta, Canada. Prostatitis with 
pyelonephritis was diagnosed, and the patient was treated 
with ertapenem, 2 g/day. Culture of a clean-catch urine 
sample taken before the ertapenem was started yielded E. 
coli MH01 at >105 CFU/mL urine. The patient improved 
clinically, and a urine culture taken after 7 days of therapy 
showed no bacterial growth. The patient received 1 dose of 
3 g fosfomycin after completing the ertapenem.
Antimicrobial drug susceptibility was determined with 
the VITEK 2 instrument (Vitek AMS; bioMérieux Vitek 
Systems, Hazelwood, MO, USA). MICs of the following 
drugs were determined: amoxicillin/clavulanic acid, pip-
eracillin/tazobactam, cefoxitin, ceftriaxone, ceftazidime, 
aztreonam, meropenem, ertapenem, amikacin, gentamicin, 
tobramycin, ciproﬂ  oxacin, and trimethoprim/sulfamethox-
azole. Additional susceptibility tests for imipenem, mero-
penem, ertapenem, tigecycline, and colistin were performed 
by using Etest (AB BioDisk, Solna, Sweden) according to 
the manufacture’s instructions. Results were interpreted by 
using Clinical and Laboratory Standards Institute (CLSI) 
criteria for broth dilution (3). Fosfomycin susceptibility 
was determined by using CLSI disk methods (3).
The sample with E. coli was screened for MBLs with 
the MBL Etest according to the manufacturer’s instruc-
tions. Isoelectric focusing was performed on freeze–thaw 
extracts on polyacrylamide gels as described (4). PCR 
ampliﬁ  cation for blaVIM, blaIMP, blaNDM, blaCTX-Ms, blaOXAs, 
blaTEMs, and blaSHV was conducted on the isolate by us-
ing a GeneAmp 9700 ThermoCycler instrument (Applied 
Biosystems, Norwalk, CT, USA) and PCR conditions and 
primers as described (4–6). The blaCTX-M was sequenced by 
using PCR conditions and primers as described (4), and 
the blaNDM was sequenced by using the following primers 
and conditions: NDM-F1: 5′-CAGCGCAGCTTGTCG-3′, 
NDM-R1: 5′-TCGCGAAGCTGAGCA-3′. The PCR pro-
gram consisted of an initial denaturation step at 95°C for 5 
min; followed by 30 cycles of DNA denaturation at 95°C 
for 1 min, primer annealing at 52°C for 1 min, and primer 
extension at 72°C for 1 min; followed by a ﬁ  nal extension 
at 72°C for 5 min.
The qnrA, qnrS, and qnrB genes were ampliﬁ  ed in 
MH01 by using multiplex PCR (7). The aac(6′)-Ib and qepA 
genes were ampliﬁ  ed in a separate PCR by using primers 
and conditions as described (8,9). The variant aac(6′)-Ib-cr 
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was further identiﬁ  ed by digestion with BstF5I (New Eng-
land Biolabs, Ipswich, MA, USA).
Multilocus sequencing typing (MLST) was performed 
on MH01 by using 7 conserved housekeeping genes (adk, 
fumC, gyrB, icd, mdh, purA, and recA). The MLST proto-
col, including allelic type and sequence type assignment 
methods, is detailed at http://mlst.ucc.ie/mlst/dbs/Ecoli.
MH01 was assigned to 1 of the 4 main E. coli phylo-
genetic groups (A, B1, B2, D) by using a multiplex PCR-
based method (10). Plasmid sizes were determined by us-
ing protocols and conditions described (11) and assigned to 
plasmid families by PCR-based replicon typing (12). Con-
jugation experiment was performed by mating-out assays 
with a selection agar containing different β-lactams (IMP 2 
μg/mL, ceftazidime 4 μg/mL respectively) and by using E. 
coli C600N as recipient.
When we used Vitek 2, E. coli MH01 was resistant 
to amoxicillin/clavulanic acid, piperacillin/tazobactam, 
cefoxitin, ceftriaxone, ceftazidime, aztreonam, meropen-
em, ertapenem, amikacin, gentamicin, tobramycin, cipro-
ﬂ   oxacin, and trimethoprim/sulfamethoxazole. The MICs 
detected by Etest were meropenem 32 μg/mL, imipenem 
32 μg/mL, ertapenem >32 μg/mL, tigecycline 0.5 μg/mL, 
and colistin 0.125 μg/ml. The zone size for fosfomycin 
was 26 mm. MH01 was susceptible only to tigecycline 
and fosfomycin; CLSI has not published colistin MICs for 
Enterobacteriaceae.
E. coli MH01 was positive for MBL production by 
MBL Etest. Isoelectric focusing showed that E. coli MH01 
produces 2 β-lactamases with isoelectric points of 5.2 and 
8.9; PCR with sequencing identiﬁ   ed these enzymes as 
NDM-1 and CTX-M-15, respectively. The isolate was pos-
itive for aac(6′)-Ib (but not aac(6′)-Ib-cr) and belonged to 
MLST clone 101 and phylogenetic group B1. E. coli MH01 
harbored 4 plasmids of 75 kb, 165 kb, 300 kb, and 400 kb. 
E. coli (MH01A) transconjugant with an MBL phenotype 
was obtained, and plasmid analysis showed that it harbored 
a 75-kb plasmid. PCR conﬁ  rmed that the transconjugant 
contained blaNDM that was untypeable by PCR-based repl-
icon typing. The blaCTX-M-15 was identiﬁ  ed on the 165-kb 
plasmid that belonged to incompatibility groups IncA/C 
and IncFII. These results were similar to those obtained by 
Poirel et al. (13).
Conclusions
Kumarasamy et al. (5) recently provided evidence that 
NDM-producing Enterobacteriaceae (mostly K. pneumo-
niae and E. coli) are widespread in the Indian subcontinent. 
They also found that many patients in the United Kingdom 
infected with bacteria that produce NDM-1 had been hos-
pitalized on the Indian subcontinent. The patients sought 
care for a variety of hospital- and community-associated 
infections; UTIs were the most common clinical infections. 
NDM-producing  Enterobacteriaceae also have recently 
been isolated from patients residing in the United States 
(14), Netherlands (15), and Australia (5); all patients had 
received medical care while visiting India.
Our ﬁ  ndings add Canada to the growing list of coun-
tries from which these bacteria have been isolated. An E. 
coli isolate with NDM-1 and belonging to the same se-
quence type has been reported from Australia from a pa-
tient previously hospitalized in Bangladesh (13). Isolation 
of the same clone in 2 patients in different countries with-
out any obvious contact underscores the probable acquisi-
tion of these bacteria during receipt of medical care in the 
subcontinent and suggests that E. coli ST101 with NDM-1 
may be widespread throughout the region. The recent pan-
demic caused by E. coli clone ST131, which produces 
CTX-M types of β-lactamases, highlights the ability of cer-
tain clones to spread rapidly. E. coli ST101 with NDM-1 
may have the potential to cause a similar pandemic.
The worldwide spread of Enterobacteriaceae-produc-
ing NDMs has serious implications for the empiric treat-
ment of hospital- and community-associated infections be-
cause of the multiresistant nature of these bacteria, which 
severely limits treatment options. Worse, few antimicrobial 
drugs being developed have activity against gram-negative 
bacteria. If the emerging public health threat of internation-
al travel in the spread of antimicrobial resistance is ignored, 
the medical community may face carbapenem-resistant 
Enterobacteriaceae that cause common infections such as 
UTIs.
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